NASDAQ: ADGMAdagio Medical Holdings Inc Stock
$0.97+0.17 (+21.25%)
Updated Dec 1, 2025
ADGM Price
$0.97
Fair Value Price
N/A
Market Cap
$20.59M
52 Week Low
$0.63
52 Week High
$2.87
P/E
-0.2x
P/B
-15.69x
P/S
217.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$137.00k
Earnings
-$79.15M
Gross Margin
-1,468.6%
Operating Margin
-55,727.01%
Profit Margin
-57,771.5%
Debt to Equity
-25.04
Operating Cash Flow
-$22M
Beta
0.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADGM Overview
ARYA Sciences Acquisition Corp IV is a "blank check" company formed to effect mergers, capital stock exchanges asset acquisitions, stock purchases, reorganizations, or similar business combinations. The Company targets the healthcare and healthcare-related sectors. ARYA Sciences Acquisition was incorporated in 2020 and is based in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADGM's potential to beat the market
- ADGM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ADGM
RankedUnranked of 109
RankedUnranked of 109
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $24.88 | A | |
| $11.52 | A | |
| $7.60 | A |
Be the first to know about important ADGM news, forecast changes, insider trades & much more!
ADGM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADGM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADGM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADGM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ADGM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ADGM due diligence checks available for Premium users.
Valuation
ADGM fair value
Fair Value of ADGM stock based on Discounted Cash Flow (DCF)
Price
$0.97
Fair Value
-$1.00
Undervalued by
196.88%
ADGM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADGM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.2x
Industry
25.87x
Market
45.08x
ADGM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-15.69x
Industry
4.02x
ADGM's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.1M
Profit Margin
0%
ADGM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADGM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.5M
Liabilities
$32.9M
Debt to equity
-25.04
ADGM's short-term liabilities ($9.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADGM's long-term liabilities ($23.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADGM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADGM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
-$520.0k
Financing
$0.0
ADGM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADGM vs Medical Device Stocks
Adagio Medical Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.